An Increase in Cell Number at Completion of Therapy May Develop As an Indicator of Early Relapse: Quantification of Circulating Epithelial Tumor Cells (CETC) for Monitoring of Adjuvant Therapy in Breast Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2007 Jul 6

PMID 17611779

Citations 9

Authors

Katharina Pachmann

Robert Dengler

Kurt Lobodasch

Frank Frohlich

Torsten Kroll

Matthias Rengsberger

Rene Schubert

Ulrich Pachmann

Affiliations

Soon will be listed here.

Abstract

Purpose: Treatment efficiency of adjuvant therapy in breast cancer is only revealed after several years by statistical evaluation and gives no answer for the individual patient. We here present a method to analyze the response to adjuvant chemotherapy online in individual patients.

Methods/results: In 25 consecutive non-metastatic primary breast cancer patients adjuvant fluorouracil/epirubicin/cyclophosphamid (FEC) or EC followed by taxane (EC-T) or cyclophosphamid/methotrexate/fluorouracil (CMF) therapy were given. Circulating epithelial tumor cells (CETC) were quantified before and after each second cycle of the therapy regimen, between the anthracycline and the taxane block of the regimen and in some cases repeatedly during CMF treatment. Independent of the initial cell number CETC numbers showed a decline, no change or a minor increase in 15 patients of which 14 remained in complete remission and 1 suffered local relapse. Ten patients showed an increase at the end of therapy of which 4 have relapsed during the observation time of between 2 months and up to 54 months. This patient group was compared to a previously published group of 25 patients who have all reached a follow-up of 4.5 years or until relapse.

Conclusion: As in the previous report, Kaplan-Meier analysis revealed a high correlation between the response of CETC to therapy and relapse (p < 0.0001) and curves of both patient groups were super imposable. Multivariate analysis revealed the response of CETC to therapy to be an independent predictive marker for relapse.

Citing Articles

Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer.

Maurer M, Schott D, Pizon M, Drozdz S, Wendt T, Wittig A Curr Oncol. 2023; 30(1):261-273.

PMID: 36661670 PMC: 9857667. DOI: 10.3390/curroncol30010021.

High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation.

Payer P, Roder M, Camara O, Pachmann K Ecancermedicalscience. 2020; 14:1003.

PMID: 32104205 PMC: 7039695. DOI: 10.3332/ecancer.2020.1003.

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging.

Willecke-Hochmuth R, Pachmann K, Drevs J Oncol Lett. 2016; 12(3):1711-1716.

PMID: 27588120 PMC: 4997972. DOI: 10.3892/ol.2016.4878.

Pharmacologic regulation of AMPK in breast cancer affects cytoskeletal properties involved with microtentacle formation and re-attachment.

Chakrabarti K, Whipple R, Boggs A, Hessler L, Bhandary L, Vitolo M Oncotarget. 2015; 6(34):36292-307.

PMID: 26431377 PMC: 4742178. DOI: 10.18632/oncotarget.5345.

Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer.

Lend A, Kazantseva A, Kivil A, Valvere V, Palm K Tumour Biol. 2014; 36(4):2473-80.

PMID: 25424701 DOI: 10.1007/s13277-014-2860-6.

References

Lobodasch K, Frohlich F, Rengsberger M, Schubert R, Dengler R, Pachmann U . Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Breast. 2007; 16(2):211-8. DOI: 10.1016/j.breast.2006.12.005. View

Pachmann K, Heiss P, Demel U, Tilz G . Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med. 2001; 39(9):811-7. DOI: 10.1515/CCLM.2001.134. View

Jones A . Reduction in mortality from breast cancer. BMJ. 2005; 330(7485):205-6. PMC: 546052. DOI: 10.1136/bmj.330.7485.205. View

Solomayer E, Diel I, Salanti G, Hahn M, Gollan C, Schutz F . Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res. 2001; 7(12):4102-8. View

Mansi J, Gogas H, Bliss J, Gazet J, Berger U, Coombes R . Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999; 354(9174):197-202. DOI: 10.1016/s0140-6736(98)10175-7. View

Naumov G, Townson J, MacDonald I, Wilson S, Bramwell V, Groom A . Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2004; 82(3):199-206. DOI: 10.1023/B:BREA.0000004377.12288.3c. View

Boucher Y, Brekken C, Suit H, Jain R . Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999; 59(15):3776-82. View

Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S . The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005; 103(5):884-91. DOI: 10.1002/cncr.20834. View

Sawyers C . Calculated resistance in cancer. Nat Med. 2005; 11(8):824-5. DOI: 10.1038/nm0805-824. View

10.

Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N . Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. 2003; 14(6):849-55. DOI: 10.1093/annonc/mdg259. View

11.

Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roche H . Taxanes in adjuvant breast cancer setting: which standard in Europe?. Crit Rev Oncol Hematol. 2005; 55(3):167-75. DOI: 10.1016/j.critrevonc.2005.04.003. View

12.

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

13.

Lara O, Tong X, Zborowski M, Chalmers J . Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol. 2004; 32(10):891-904. DOI: 10.1016/j.exphem.2004.07.007. View

14.

Bonadonna G, Moliterni A, Zambetti M, Daidone M, Pilotti S, Gianni L . 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005; 330(7485):217. PMC: 546063. DOI: 10.1136/bmj.38314.622095.8F. View

15.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

16.

Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K . Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report. World J Surg Oncol. 2005; 3(1):18. PMC: 1087511. DOI: 10.1186/1477-7819-3-18. View

17.

Feldman M, Stanford R, Catcheside A, Stotter A . The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer. Eur J Surg Oncol. 2002; 28(6):615-9. DOI: 10.1053/ejso.2002.1300. View

18.

Pachmann K . Longtime recirculating tumor cells in breast cancer patients. Clin Cancer Res. 2005; 11(15):5657. DOI: 10.1158/1078-0432.CCR-05-0191. View

19.

Pierga J, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N . Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004; 10(4):1392-400. DOI: 10.1158/1078-0432.ccr-0102-03. View

20.

Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K . Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res. 2005; 24(6):4211-6. View